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Mesenchymal stem cells (MSC) were 
identified in the 1960s as bone marrow 
cells capable of osteogenic differentiation 
(Friedenstein and Petrakova, 1966). In the 
following decennia, these cells were further 
attributed with the capacity to differentiate 
into adipogenic, chondrogenic, and myo-
genic lineages (Pittenger et al., 1999), to 
secrete trophic factors that stimulate other 
cell types (Caplan and Dennis, 2006), and 
to possess immunomodulatory properties 
(Di Nicola et al., 2002). Cells with these 
properties were found not to be restricted 
to the bone marrow, but also to reside at 
other locations including adipose tissue 
(Zuk et al., 2002), skin (Toma et al., 2001), 
and in organs like liver, kidney, and brain 
(da Silva Meirelles et al., 2006). In particular 
adipose tissue has proven to be a valuable 
source of MSC due to its accessibility and 
its abundance.
The characteristics of MSC initiated 
interest in their potential clinical use for 
tissue regenerative and immunomodula-
tory purposes. The first clinical applica-
tions were in the treatment of osteogenesis 
imperfecta (Horwitz et al., 1999) and graft 
versus host disease (Le Blanc et al., 2004). 
Since then, the use of MSC for the treatment 
of a variety of diseases has been investigated 
in clinical trials, including in Crohn’s dis-
ease (Duijvestein et al., 2010), myocardial 
infarction (Hare et al., 2009), rheumatoid 
arthritis (Liang et al., 2011), multiple scle-
rosis (Freedman et al., 2010), and organ 
transplantation (Dahlke et al., 2009).
In organ transplantation, the use of MSC 
is aimed at the prolongation of allograft sur-
vival. Thus, MSC therapy may be used for 
the treatment of acute rejection, but also 
to prevent currently untreatable chronic 
rejection. Furthermore, there is evidence 
that MSC therapy has a tissue regenerative 
component that repairs organ injury caused 
by immunological or ischemic events and 
thereby prevents the loss of organ trans-
plants in animal models (Morigi et al., 2008; 
Popp et al., 2008). This may offer another 
window of opportunity for MSC therapy 
in particular shortly after transplanta-
tion, when organ loss peaks partly due to 
ischemia–reperfusion injury of the graft.
As with all therapies in development, 
the reasons for the use of MSC as an 
immunomodulatory and regenerative 
agent should be taken into careful consid-
eration. Open questions are whether MSC 
therapy is effective and, if so, whether it 
is more efficient than existing drugs? Are 
there safety issues involved? Is MSC therapy 
cost-effective? Whether MSC can replace 
existing drugs is not clear at the moment 
as the efficacy of MSC therapy is difficult 
to determine. A one to one comparison of 
efficacy between MSC and conventional 
drugs is not easy to make. While pharma-
cological drugs target specific molecular 
pathways, MSC have a wide range of effects. 
Furthermore, while pharmaceuticals can 
be given to patients at a daily frequency, 
for safety, practical, and financial reasons 
there is a limit to the frequency at which 
cell therapy can be applied. However, at 
these early stages, a head on comparison 
with standard therapy may not be required 
as the use of MSC will primarily be aimed 
at applications where conventional thera-
pies fail. As such, MSC will be applied as 
an adjuvant for current therapies. In the 
more distant future, MSC may be used 
to replace medication that has significant 
side effects, as may be the case with cal-
cineurin inhibitors in organ transplanta-
tion. Although very effective in preventing 
organ rejection, calcineurin inhibitors 
are nephrotoxic, thereby limiting the life 
span of kidney transplants. Side effects of 
MSC therapy have not been reported yet, 
but certainly some will occur when MSC 
are used more widely. A high incidence of 
infections after MSC therapy in graft versus 
host disease patients was recently reported 
(von Bahr et al., 2011). Whether the risk for 
infection was significantly elevated in MSC 
treated patients compared to controls was 
however not demonstrated. To be able to 
map the side effects of MSC therapy, these 
effects should be investigated parallel to 
their clinical effects in placebo-controlled 
studies. Nevertheless, from where we stand 
today, we can conclude with considerable 
certainty that the infusion of MSC does not 
harbor serious health threats.
While the in vitro properties of MSC sug-
gest a beneficial effect of MSC in immu-
nological and degenerative diseases and 
early clinical trials are triumphant about 
the feasibility and safety of MSC therapy, 
there is thus far little evidence that MSC 
are effective in curing disease. The effec-
tiveness of MSC therapy needs to be estab-
lished in follow up trials and knowledge of 
the mechanisms of action of MSC may help 
optimizing the therapy. The mechanisms of 
action of MSC after infusion may be very 
different to those observed in vitro. There 
is for instance accumulating evidence that 
MSC are short-lived after infusion (Popp 
et al., 2008). Even though, long-term effects 
are observed after infusion of MSC. These 
effects may be mediated by other cell types 
to which the effect of MSC is transferred. 
It has been demonstrated that MSC induce 
immunoregulatory capacity of T cells 
(Prevosto et al., 2007) and macrophages 
(Maggini et al., 2010). More knowledge 
on how MSC interact with these cell types 
could provide tools for optimizing MSC 
therapy.
An alternative approach for MSC ther-
apy is to design drugs or therapies that tar-
get tissue resident MSC. MSC respond to 
cytokines and growth factors by changing 
their immunoregulatory function and/or 
their differentiation status. Therefore, these 
factors could be the basis of such drugs, 
which should induce a specific response in 
MSC that reside in transplanted organs. In 
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In order for a therapy to be successful, it 
needs to be cost-effective. MSC treatment is 
a costly therapy as MSC need to be cultured 
under GMP conditions. In particular the 
generation of custom-made, i.e., autolo-
gous, MSC of clinical grade is an expensive 
process. Centralization of MSC production 
at specialized laboratories can reduce costs. 
Furthermore, for some applications alloge-
neic MSC may be suitable and these can be 
generated in large batches, which further 
brings down costs. A real cost–effect analysis 
can however only be made once the efficacy 
of MSC therapy has become clear.
Summarizing, MSC have the potential 
to be used as an immunomodulatory and 
regenerative therapy in organ transplanta-
tion and immune and degenerative diseases. 
Basic and clinical research will have to point 
toward the right directions on the effec-
tive use of MSC. In this special feature of 
Frontiers in Immunology, the most recent 
findings on the immunomodulatory capac-
ity of MSC, such as their interaction with 
regulatory T cells, and on their potential 
to induce regeneration of liver, kidney, and 
heart after ischemia–reperfusion injury and 
of bone and cartilage damage in rheuma-
toid and osteoarthritis, will be presented. 
Furthermore, challenges on how to generate 
a high quality and effective cell product will 
receive attention. Finally, the use of MSC in 
transplantation and regenerative medicine 
and ideas on how to drive this field forward 
will be reviewed and discussed by leaders in 
the field. We are confident that this special 
topic will generate new directions to be fol-
lowed in translational research and clinical 
trials.
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